[Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
D000328:Adult; D000368:Aged; D000818:Animals; D001923:Brain Chemistry; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004298:Dopamine / Q000032:analysis; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D007980:Levodopa / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D011736:Pyridoxine / Q000008:administration & dosage* / Q000627:therapeutic use; D051381:Rats
D007980:Levodopa; D006897:Hydroxyindoleacetic Acid; D002262:Carboxy-Lyases; D011736:Pyridoxine; D004298:Dopamine